Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment...

Area of Science:

• Pharmacology
• Oncology
• Hematology

Background:

• Cancer patients face high risks of venous thromboembolism (VTE).
• Low-molecular-weight heparins (LMWHs) are recommended for cancer-associated thrombosis.
• Limited LMWH options were previously approved in the European Economic Area (EEA).

Purpose of the Study:

• To compare the benefit-risk profile of enoxaparin with dalteparin and tinzaparin.
• To evaluate enoxaparin for extended treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in active cancer patients.
• To assess enoxaparin's efficacy in preventing VTE recurrence in this population.

Main Methods:

• A semi-quantitative benefit-risk assessment framework was utilized.
• Key benefit outcomes included reduced all-cause mortality and VTE recurrence.
• Key risk outcomes included major/non-major bleeding and heparin-induced thrombocytopenia (HIT).

Main Results:

• Enoxaparin demonstrated comparable efficacy to dalteparin and tinzaparin in reducing VTE recurrence and all-cause mortality.
• No significant differences in major or non-major bleeding incidence were observed between enoxaparin and comparators.
• Data on HIT were insufficient for a comparative assessment.

Conclusions:

• Enoxaparin exhibits a favorable benefit-risk profile for treating DVT and PE in cancer patients.
• Its profile is similar to other EEA-approved LMWHs, supporting its extended use.
• The findings support the label-extension approval of enoxaparin for this indication.